Commercial vaccines are a vital part of any dairy health protocol, but sometimes disease prevention requires a different approach. Newport Laboratories, Inc., creates custom-made vaccines designed to help fight the specific pathogens challenging your clients’ herd, ensuring your veterinary toolbox is always complete.

Learn more about custom-made vaccines at NewportLabs.com.
AVMA DELEGATE: Brian J. Gerloff, DVM
Marengo, Illinois

ADVERTISING AGENCY: J. T. O’Brien & Assoc.
12118 Nieman Road
Overland Park, Kansas 66213
(913) 579-4084

THE BOVINE PRACTITIONER is published by The American Association of Bovine Practitioners, at VM Publishing Company, LLC, 205 W. 7th, Suite 201, Stillwater, OK 74074 (Telephone and Fax: (405) 533-1883). Copies are mailed to veterinarians engaged in cattle practice and allied institutions. Send new address (please include old address) to:

AABP
1130 East Main Street, Suite 302
Ashland, Ohio 44805
Tel: (419) 496-0685; FAX (419) 496-0697
e-mail: aabphq@aabp.org
http://www.aabp.org

THE BOVINE PRACTITIONER is the official publication of The American Association of Bovine Practitioners, published in the spring and summer annually. It serves as a communication medium between bovine practitioner organizations around the world. All manuscripts and communications must be presented in English. Beginning in 2019, THE BOVINE PRACTITIONER is an open access journal. Copies of THE BOVINE PRACTITIONER are available to non-members. Contact editor for details and subscription prices.

©American Association of Bovine Practitioners, 2020 • All Rights Reserved • The Bovine Practitioner • ISSN 0524-1685

© Copyright American Association of Bovine Practitioners; open access distribution.
BVD VIRUS TYPE 1B IS ON THE RISE.

Bovine viral diarrhea (BVD) infection can disintegrate herd productivity. And if you're using a vaccine, like Bovi-Shield GOLD®, that isn't labeled for the most prevalent strain, your cattle could be at risk. Play it safe. Choose the only vaccines specifically labeled to protect against Type 1b: Express® FP and Pyramid® + Presponse® SQ. Know more at BVDVTracker.com.


EXPRESS®, PYRAMID®, The PYRAMID Logo® and PRESPONSE® are registered trademarks of Boehringer Ingelheim Animal Health USA Inc. The EXPRESS logo™ is a trademark of Boehringer Ingelheim Vetmedica GmbH, used under license. All other trademarks are property of their respective owners. ©2020 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All Rights Reserved. US-BOV-0284-2019A-V2
Metaphylaxis with tildipirosin did not inhibit effectiveness of an experimental monovalent vaccine of live, attenuated *Mannheimia haemolytica* administered intranasally to dairy calves.

Scott Nordstrom, Michael Bolton, Kevin Hill, Tim Parks, Mani Vaidyanathan, Geert Vertenten, Kelly Lechtenberg

Efficacy of a modified-live IBR-BVD-PI3-BSV-Mannheimia haemolytica toxoid vaccine against challenge with virulent BHV-1 and PI3 viruses in calves 60 days of age.

Aleksandar Masic, Suman Mahan, Brian Sobecki, Chadwick Brice, Sally Mattern, Dennis Peterson, Peter Barret, Colt Daugherty, Todd Meinert, Correas Ignacio, Moulin Véronique

The impact of future technological advancements on current bovine respiratory disease management practices.

Jason S. Nickell, Lonty K. Bryant, Robert P. Lavan, Pedro Rodriguez Fernandez

Advertisers Index

Addison Biological Laboratory, Inc. ........................................................................................................................................... inside front cover
Boehringer Ingelheim Animal Health Inc. US ........................................................................................................................................................................... table of contents, back cover
Merck Animal Health ...................................................................................................................................................................................... front of book

Cover photo courtesy of Jennifer L. Nightingale, DVM, Countryside Veterinary Clinic, Lowville, NY.

Notice to Readers

All statements, opinions and conclusions contained in articles in *The Bovine Practitioner* are those of the author(s), and are not necessarily those of the American Association of Bovine Practitioners (AABP) unless specifically approved by the AABP Board of Directors.
The Bovine Practitioner articles are reviewed by three Editorial Review Board members. 

Reviewers for 2020 included:

Dr. David Anderson  
Knoxville, TN

Dr. Kevin Anderson  
Raleigh, NC

Dr. Chance Armstrong  
Baton Rouge, LA

Dr. Ruth Blauwiekel  
Colchester, VT

Dr. Robert Callan  
Ft. Collins, CO

Dr. Vickie L. Cooper  
Ames, IA

Dr. Robert Corbett  
Spring City, UT

Dr. Brent Credille  
Bishop, GA

Dr. Russ Daly  
Brookings, SD

Dr. Lionel Dawson  
Stillwater, OK

Dr. Andre Desrochers  
St-Hyacinthe, Quebec, Canada

Dr. Renee Dewell  
Ames, IA

Dr. Grant Dewell  
Ames, IA

Dr. Tyler Dohlman  
Ames, IA

Dr. Terry Engelken  
Ames, IA

Dr. Charles Estill  
Corvallis, OR

Dr. David Foster  
Raleigh, NC

Dr. Franklyn Garry  
Ft. Collins, CO

Dr. Philippa Gibbons  
Speedwell, TN

Dr. John Gilliam  
Stillwater, OK

Dr. Sandra Godden  
St. Paul, MN

Dr. Pat Gorden  
Ames, IA

Dr. Meggan Graves  
Knoxville, TN

Dr. Dee Griffin  
Canyon, TX

Dr. Larry C. Holis  
Flint, TX

Dr. Richard Hopper  
Auburn, AL

Dr. Andy Johnson  
Green Bay, WI

Dr. Meredyth Jones  
Perkins, OK

Dr. Erin King  
Woodstock, CT

Dr. Jennifer Koziol  
West Lafayette, IN

Dr. Brian Lubbers  
Manhattan, KS

Dr. Kaitlyn Lutz  
Geneva, NY

Dr. Matt Miesner  
Manhattan, KS

Dr. Dale Moore  
Moscow, ID

Dr. Pierre-Yves Mulon  
Knoxville, TN

Dr. Christine Navarre  
Baton Rouge, IA

Dr. Terri Ollivett  
Madison, WI

Dr. Craig Payne  
Columbia, MO

Dr. Dan Posey  
Amarillo, TX

Dr. D. Owen Rae  
Gainesville, FL

Dr. Ryan Rademacher  
Okotoks, Alberta, Canada

Dr. Emily Reppert  
Manhattan, KS

Dr. John Richeson  
Canyon, TX

Dr. Karen Rogers  
Greeley, CO

Dr. Emmanuel Rollin  
Athens, GA

Dr. Allen Roussel  
College Station, TX

Dr. Loren Schultz  
Columbia, MO

Dr. Jan Shearer  
Ames, IA

Dr. Katie Simpson  
Fort Collins, CO

Dr. David Smith  
Mississippi State, MS

Dr. Lynn Steadman  
Chadron, NE

Dr. Gerald Stokka  
Cooperstown, ND

Dr. Bill Stone  
Auburn, NY

Dr. Anthony Tarploff  
Manhattan, KS

Dr. Dan Thomson  
Ames, IA

Dr. Michael Van Amburgh  
Ithaca, NY

Dr. Brian Vander Ley  
Clay Center, NE

Dr. Kevin Washburn  
College Station, TX

Dr. Lou Anne Wolfe  
Claremore, OK

Appreciation is extended to each board member for volunteering their time and expertise to review articles for The Bovine Practitioner.

© Copyright American Association of Bovine Practitioners; open access distribution.
When you spot bovine respiratory disease (BRD), reach for the fast that lasts.

Reaching peak plasma levels in 45 minutes, ZUPREVO gets to work rapidly. Its unique chemical structure results in swift accumulation in the lungs and keeps working for 28 days in lung tissue.1 With ZUPREVO, you can give clients the therapy they need to win the race against BRD. Fast-acting, long-lasting solutions are another way Merck Animal Health Works for you and your clients.

See the full prescribing information at Zuprevo.com.

PRODUCT INFORMATION
NADA 141-334, Approved by FDA.

ZUPREVO® 18%
Injectable Solution for Cattle

ANTIMICROBIAL DRUG
180 mg of tildipirosin/mL. For subcutaneous injection in beef and non-lactating dairy cattle only.

Not for use in female dairy cattle 20 months of age or older or in calves to be processed for veal.

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

BRIEF SUMMARY: For full prescribing information use package insert.

INDICATIONS: Zuprevo® 18% is indicated for the treatment of bovine respiratory disease (BRD) associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in beef and non-lactating dairy cattle and for the control of respiratory disease in beef and non-lactating dairy cattle at high risk of developing BRD associated with M. haemolytica, P. multocida, and H. somni.

WARNINGS: FOR USE IN ANIMALS ONLY. NOT FOR HUMAN USE. KEEP OUT OF REACH OF CHILDREN. TO AVOID ACCIDENTAL INJECTION, DO NOT USE IN AUTOMATICALLY POWERED SYRINGES WHICH HAVE NO ADDITIONAL PROTECTION SYSTEM. IN CASE OF HUMAN INJECTION, SEEK MEDICAL ADVICE IMMEDIATELY AND SHOW THE PACKAGE INSERT OR LABEL TO THE PHYSICIAN.

Avoid direct contact with skin and eyes. If accidental eye exposure occurs, rinse eyes with clean water. If accidental skin exposure occurs, wash the skin immediately with soap and water. Tildipirosin may cause sensitization by skin contact.

For technical assistance or to report a suspected adverse reaction, call: 1-800-219-9286.

For customer service or to request a Material Safety Data Sheet (MSDS), call: 1-800/211-3573. For additional Zuprevo 18% information go to www.zuprevo.com.

For a complete listing of adverse reactions for Zuprevo 18% reported to CVM see: http://www.fda.gov/AnimalVeterinary/SafetyHealth.

DO NOT USE ZUPREVO 18% IN SWINE.
Fatal adverse events have been reported following the use of tildipirosin in swine. NOT FOR USE IN CHICKENS OR TURKEYS.

RESIDUE WARNING: Cattle intended for human consumption must not be slaughtered within 21 days of the last treatment. Do not use in female dairy cattle 20 months of age or older. Use of this drug product in these cattle may cause milk residues. A withdrawal period has not been established in pre-ruminating calves. Do not use in calves to be processed for veal.

PRECAUTIONS: The effects of Zuprevo 18% on bovine reproductive performance, pregnancy and lactation have not been determined. Swelling and inflammation, which may be severe, may be seen at the injection site after administration. Subcutaneous injection may result in local tissue reactions which persist beyond the slaughter withdrawal period. This may result in trim loss of edible tissue at slaughter.
Moraxella bovoculi Bacterin

World's First Commercially Available Moraxella bovoculi Pinkeye Preventative!

• 8 Different M. bovoculi Isolates
• Cost Effective for All Cattle Herds
• Proven Safety Record
• More Convenient than Autogenous Programs

Addison Biological Laboratory, Inc. announces the approval of the world's first commercial Moraxella bovoculi vaccine for the prevention of pinkeye in cattle. The USDA conditionally licensed product is the first of this kind. Previously the only method of prevention against Moraxella bovoculi was autogenous vaccines. This vaccine signifies a breakthrough in convenience for the large number of veterinarians and herd owners battling the challenging problem of pinkeye caused by Moraxella bovoculi. The product license is conditional; efficacy and potency have not been fully demonstrated.

From the LEADERS in pinkeye prevention!

Addison Biological Laboratory, Inc.  
www.addisonlabs.com  
info@addisonlabs.com  
800-331-2530